186 related articles for article (PubMed ID: 19416226)
1. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
[TBL] [Abstract][Full Text] [Related]
2. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.
Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
J Card Fail; 2009 Apr; 15(3):182-90. PubMed ID: 19327619
[TBL] [Abstract][Full Text] [Related]
3. Relaxin: a new approach for the treatment of acute congestive heart failure.
Grossman J; Frishman WH
Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
[TBL] [Abstract][Full Text] [Related]
4. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis.
Seibold JR; Clements PJ; Furst DE; Mayes MD; McCloskey DA; Moreland LW; White B; Wigley FM; Rocco S; Erikson M; Hannigan JF; Sanders ME; Amento EP
J Rheumatol; 1998 Feb; 25(2):302-7. PubMed ID: 9489823
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effect of recombinant human brain natriuretic peptide for treatment of decompensated heart failure: comparison with nitroglycerin].
Xie CL; Meng SR; Wang W; Chen SM; Li P; Feng XG
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):839-42. PubMed ID: 18504215
[TBL] [Abstract][Full Text] [Related]
7. Design of the RELAXin in acute heart failure study.
Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
[TBL] [Abstract][Full Text] [Related]
8. Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats.
Danielson LA; Conrad KP
J Appl Physiol (1985); 2003 Oct; 95(4):1509-14. PubMed ID: 12819218
[TBL] [Abstract][Full Text] [Related]
9. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
Kumar VA; Wilson SS; Ayaz SI; Levy PD
Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
[TBL] [Abstract][Full Text] [Related]
10. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
[TBL] [Abstract][Full Text] [Related]
11. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
12. Effect of short-term infusion of recombinant human relaxin on blood pressure in the late-pregnant rhesus macaque (Macaca mulatta).
Golub MS; Working PK; Cragun JR; Cannon RA; Green JD
Obstet Gynecol; 1994 Jan; 83(1):85-8. PubMed ID: 8272314
[TBL] [Abstract][Full Text] [Related]
13. Serelaxin : a potential new drug for the treatment of acute heart failure.
Neverova N; Teerlink JR
Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
[TBL] [Abstract][Full Text] [Related]
15. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
Khanna D; Clements PJ; Furst DE; Korn JH; Ellman M; Rothfield N; Wigley FM; Moreland LW; Silver R; Kim YH; Steen VD; Firestein GS; Kavanaugh AF; Weisman M; Mayes MD; Collier D; Csuka ME; Simms R; Merkel PA; Medsger TA; Sanders ME; Maranian P; Seibold JR;
Arthritis Rheum; 2009 Apr; 60(4):1102-11. PubMed ID: 19333948
[TBL] [Abstract][Full Text] [Related]
18. Top heart-failure contender serelaxin flops.
Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398333
[No Abstract] [Full Text] [Related]
19. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?
Dschietzig TB
Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696
[TBL] [Abstract][Full Text] [Related]
20. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
